Last reviewed · How we verify
Thymosin Alpha 1
Thymosin Alpha 1 is an immunomodulatory peptide that enhances T-cell maturation and immune function by promoting thymic differentiation and activation of immune cells.
Thymosin Alpha 1 is an immunomodulatory peptide that enhances T-cell maturation and immune function by promoting thymic differentiation and activation of immune cells. Used for Chronic hepatitis B, Chronic hepatitis C, Immunodeficiency states.
At a glance
| Generic name | Thymosin Alpha 1 |
|---|---|
| Also known as | thymalfasin, thymosin α, Zadaxin, Thymosin Group |
| Sponsor | Xuanwu Hospital, Beijing |
| Drug class | Immunomodulator |
| Target | T-cell maturation pathway / thymic differentiation |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Thymosin Alpha 1 is a naturally occurring peptide derived from the thymus gland that acts as an immunomodulator. It enhances T-cell development and maturation, increases natural killer cell activity, and promotes the production of cytokines that support immune responses. The drug is used to restore or enhance immune function in patients with compromised immunity or chronic infections.
Approved indications
- Chronic hepatitis B
- Chronic hepatitis C
- Immunodeficiency states
- Recurrent infections
Common side effects
- Injection site reactions
- Fever
- Fatigue
- Headache
Key clinical trials
- Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma (PHASE2)
- Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma (PHASE2)
- AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection (NA)
- The Safety, Tolerability, and Efficacy of KD01 in Gynecologic Malignancies (PHASE1)
- A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer (PHASE2)
- Protective Effect of Ulinastatin and Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA XI) (NA)
- The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC (PHASE2)
- Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Thymosin Alpha 1 CI brief — competitive landscape report
- Thymosin Alpha 1 updates RSS · CI watch RSS
- Xuanwu Hospital, Beijing portfolio CI